Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125 -1.32% 9.375 9.00 9.75 9.50 9.375 9.50 553,795 15:59:50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.1 -4.4 - 23

Futura Medical Share Discussion Threads

Showing 18826 to 18842 of 18850 messages
Chat Pages: 754  753  752  751  750  749  748  747  746  745  744  743  Older
DateSubjectAuthorDiscuss
02/4/2020
08:57
jonnybig2 Apr '20 - 08:41 - 7362 of 7362 (Filtered) thebutler2 Apr '20 - 08:18 - 7360 of 7362 (Filtered) so much quieter now. I have no issues with people putting different viewpoints across, but I do prefer intelligent debate....
keifer derrin
02/4/2020
08:29
It's so nice of jonnybutler to turn up together just to advise us all just how bad this company is. On the front line. Using their precious time just to berate FUM. I'm sure they must be very busy travelling the internet giving advise on all the bad investments out there. Like Fatman and Blobbin! on a crusade to save all investors millions. We should all hope THEY get the clap from the nation Thursday at 8. ;)
firedriver
02/4/2020
08:18
Yes, jonny, all you need to do is look at the chart to see what's happened here. Just a case of how much longer they squeeze money out of their stupid shareholders. Maybe they'll start to twig when FUM have reached MED5000, the placebo of the placebo of the placebo. Rolleyes and laugh out loud.
thebutler
01/4/2020
22:00
Sp continues to bounce on all time low. The thread header should now be changed to "futura bust in 2020"
jonnybig
01/4/2020
16:51
Futura Medical CEO talks regulatory timeline and commercial potential for breakthrough gel Futura Medical PLC's (LON:FUM) James Barder caught up with Proactive London's Andrew Scott on the back of their 2019 results. He says the EU filing for MED3000 is likely by the end of July, with the US Food & Drug Administration submission expected by the end of the third quarter. MED3000 is Futura's fast-acting gel for erectile dysfunction.
christh
01/4/2020
15:39
The good news is armed with phase 3 results and the subsequent data analysis they will now firm up commercial negotiations. 10 bagger material
j777j
01/4/2020
15:07
Buyers are going to be attracted to the fact that FUM will not be impacted by the coronavirus and a solid investment now. A faster return compared to investing in a large amount of industries now. Very happy with their announcements today and a structural path to market and returns to the share price from the summer last year
tiananmen
01/4/2020
14:59
Haven't seen the webcast yet, but the results looked pretty good to me. Pity about the Barder factor - without that the share price would probably be motoring along very nicely...
supernumerary
01/4/2020
11:49
just for a change didn't seem too bad to me pity it took so long and so much dosh to realise the placebo Dermasys was just as good as Med2005 however we are where we are now with Med3000 which seems to have 'prospects' although I seem to have heard before somewhere about 'discusions with prospective partners' - let's hope Futura is not naively being taken for a ride yet again by established industry majors protecting their product range - they need to get one of the members of Dragons Den in on the act
mikethebike4
01/4/2020
11:07
Tax rebate Today 10:21 It is expected that an R&D Tax Credit of £2.22 million will be claimed in respect of 2019 and the cash refund is expected to be received mid-2020 from HMRC.
christh
01/4/2020
10:52
Futura Medical confirms regulatory timeline for breakthrough gel; excited about its commercial potential “Following positive feedback after consultations with regulators we are confident MED3000 has a well-defined path to approval as a medical device as a clinically proven ED [erecrtile dsyfunction] therapy,” said chief executive James Barder Futura Medical PLC (LON:FUM) said it is “increasingly excited” about the commercial potential of its fast-acting gel for erectile dysfunction as discussions with potential partners continue “in earnest”. With its annual results, Futura confirmed that the EU filing for MED3000 is likely by the end of July, with the US Food & Drug Administration submission expected by the end of the third quarter. “Following positive feedback after consultations with regulators we are confident MED3000 has a well-defined path to approval as a medical device as a clinically proven ED [erecrtile dsyfunction] therapy,” chief executive James Barder said in the statement. “Futura remains in consultation with the FDA regarding overall data requirements as we move towards targeted regulatory submissions for MED3000 in both the US and EU in the next six months.” In the update, Futura said it had just over £2.5mln at the December 31 period-end, topped up in January by a fundraiser that brought in a gross £3.25mln. This provides a “cash runway” into the second quarter of next year, thanks to significantly reduced spending of research and development, Futura said. The medical technology group told investors it was anticipating “limited impact” from the coronavirus (COVID-19) outbreak that has forced Britain into lockdown. Futura has developed a method of delivering a medicinal payload through the skin that can be used in harness with a host of drugs. Its topical pain and inflammation relief product, TPR100, is the subject of “formulation dosing adjustment” as it and partner Thornton & Ross seek its regulatory sign-off. There are “ongoing commercial discussions” with several overseas distributors, the firm said. As is common for a company carrying out significant R&D, Futura booked a loss of £8.92mln for 2019, up from £5.88mln. www.proactiveinvestors.co.uk/companies/news/916304/futura-medical-confirms-regulatory-timeline-for-breakthrough-gel-excited-about-its-commercial-potential-916304.html
christh
01/4/2020
09:00
Looking forward to Webcast: The Executive Team will host a webcast of the presentation which will be available within the Investor Centre section of the Futura company website at www.futuramedical.com from 10am on 1 April 2020. The webcast will also include an update following the extensive internal evaluation of the clinical data from the Phase 3 study (FM57) announced on 10 December 2019, which was previously planned to be presented at the Investor Seminar on 26 March which was cancelled due to COVID-19. The Company will provide an update on ongoing research and analysis of FM57 and MED3000
qui quaerit reperit
01/4/2020
08:26
Deja Vu here..been going on for years
jailbird
01/4/2020
08:23
The Market is saying SELL. the rampers are saying takeover. Hmmmmm, who to believe LOL
thebutler
01/4/2020
08:15
butler, close your short FUM will blow all shorts today at presentation!!!!
qui quaerit reperit
01/4/2020
08:12
Indeed, takeover on cards, what price they will pay??? 40-50p???
qui quaerit reperit
01/4/2020
08:03
MED3000 will be approved and marketted. FUM probably takenover
christh
Chat Pages: 754  753  752  751  750  749  748  747  746  745  744  743  Older
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200402 19:25:06